[PDF] Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen? | Semantic Scholar Skip to search formSkip to main content> Semantic Scholar's Logo Search Sign InCreate Free Account You are currently offline. Some features of the site may not work correctly. DOI:10.3949/ccjm.79.s2.07 Corpus ID: 38910996Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen? @article{Videtic2012LocallyAN, title={Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen?}, author={G. Videtic}, journal={Cleveland Clinic Journal of Medicine}, year={2012}, volume={79}, pages={S32 - S37} } G. Videtic Published 2012 Medicine Cleveland Clinic Journal of Medicine The optimal chemoradiation regimen for patients with locally advanced non–small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a “one size fits all” approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to… Expand View on Cleveland Clinic mdedge.com Save to Library Create Alert Cite Launch Research Feed Share This Paper 11 CitationsBackground Citations 4 View All Figures and Topics from this paper figure 1 figure 2 Non-Small Cell Lung Carcinoma Chemoradiotherapy Small cell carcinoma of lung Lung consolidation Chemotherapy Seizures unresectable 11 Citations Citation Type Citation Type All Types Cites Results Cites Methods Cites Background Has PDF Publication Type Author More Filters More Filters Filters Sort by Relevance Sort by Most Influenced Papers Sort by Citation Count Sort by Recency Proton therapy for non-small cell lung cancer: the road ahead. E. Brooks, M. Ning, V. Verma, X. Zhu, J. Chang Medicine Translational lung cancer research 2019 6 View 1 excerpt, cites background Save Alert Research Feed The effect of radiotherapy dose on survival in stage III non-small-cell lung cancer patients undergoing definitive chemoradiotherapy. M. Koshy, R. Malik, +4 authors R. Weichselbaum Medicine Clinical lung cancer 2014 8 Save Alert Research Feed Inhibiting glucosylceramide synthase facilitates the radiosensitizing effects of vinorelbine in lung adenocarcinoma cells. W. Chiu, H. H. Chen, +5 authors Chiou-Feng Lin Medicine Cancer letters 2014 7 View 1 excerpt, cites background Save Alert Research Feed Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma V. Pandey, K. R. Gajbhiye, V. Soni Medicine Drug delivery 2015 25 View 1 excerpt, cites background Save Alert Research Feed An analysis of the immune phenotypes of HLA2DR, CD80 and CD83 for the DCs and of CD3, CD8 and CD56 for the CIK 2013 Save Alert Research Feed Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients Y. Cui, Xuejing Yang, W. Zhu, J. Li, Xiaojing Wu, Y. Pang Medicine Oncology letters 2013 37 PDF Save Alert Research Feed EGCG Enhances the Efficacy of Cisplatin by Downregulating hsa-miR-98-5p in NSCLC A549 Cells Dong-Hu Zhou, X. Wang, Q. Feng Chemistry, Medicine Nutrition and cancer 2014 51 View 2 excerpts, cites background Save Alert Research Feed Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. H. Jiang, Pengjun Zhao, D. Su, J. Feng, S. Ma Medicine, Biology Molecular medicine reports 2014 66 Save Alert Research Feed Combination of Low Concentration of (−)-Epigallocatechin Gallate (EGCG) and Curcumin Strongly Suppresses the Growth of Non-Small Cell Lung Cancer in Vitro and in Vivo through Causing Cell Cycle Arrest Dong-Hu Zhou, X. Wang, Mingmin Yang, X. Shi, Wenbin Huang, Q. Feng Medicine International journal of molecular sciences 2013 50 PDF Save Alert Research Feed Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. F. Asselbergs, Y. Guo, +167 authors F. Drenos Biology, Medicine American journal of human genetics 2012 207 PDF Save Alert Research Feed ... 1 2 ... References SHOWING 1-10 OF 24 REFERENCES SORT BYRelevance Most Influenced Papers Recency Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Neil A Bayman, F. Blackhall, P. Jain, L. Lee, N. Thatcher, C. Faivre-Finn Medicine Clinical lung cancer 2008 24 Save Alert Research Feed Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. K. Albain, J. Crowley, +5 authors R. Livingston Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 300 Save Alert Research Feed Concurrent chemoradiotherapy in non-small cell lung cancer. N. O’Rourke, Marta Roqué I Figuls, Nuria Farré Bernadó, F. Macbeth Medicine The Cochrane database of systematic reviews 2010 357 Save Alert Research Feed Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. C. Belani, H. Choy, +4 authors W. Curran Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 366 Save Alert Research Feed Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. N. Hanna, M. Neubauer, +17 authors L. Einhorn Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 389 Save Alert Research Feed Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. R. Govindan, J. Bogart, X. Wang, L. Hodgson, R. Kratzke, E. Vokes Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009 44 Save Alert Research Feed Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504) D. Gandara, K. Chansky, L. Gaspar, K. Albain, P. Lara, J. Crowley Medicine 2005 24 Save Alert Research Feed Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. W. Sause, P. Kolesar, +8 authors A. Turrisi Medicine Chest 2000 242 PDF Save Alert Research Feed Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. A. Aupérin, C. le Péchoux, +15 authors J. Pignon Medicine Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 1,176 Save Alert Research Feed Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. W. Sause, C. Scott, +7 authors A. Turrisi Medicine Journal of the National Cancer Institute 1995 654 Save Alert Research Feed ... 1 2 3 ... Related Papers Abstract Figures and Topics 11 Citations 24 References Related Papers Stay Connected With Semantic Scholar Sign Up About Semantic Scholar Semantic Scholar is a free, AI-powered research tool for scientific literature, based at the Allen Institute for AI. Learn More → Resources DatasetsSupp.aiAPIOpen Corpus Organization About UsResearchPublishing PartnersData Partners   FAQContact Proudly built by AI2 with the help of our Collaborators Terms of Service•Privacy Policy The Allen Institute for AI By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License ACCEPT & CONTINUE